Duality Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Duality Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,844	Closed	-$2.11M	–	674
2023 Q1	$2.11M	Buy	+20,844	New	+$2.17M	0.24%	155
2022 Q2	–	Sell	-7,729	Closed	-$725K	–	770
2022 Q1	$725K	Sell	7,729 -3,319	-30%	-$281K	0.08%	403
2021 Q4	$941K	Buy	+11,048	New	+$1.02M	0.1%	308
2021 Q2	–	Sell	-3,372	Closed	-$328K	–	673
2021 Q1	$328K	Sell	3,372 -7,920	-70%	-$831K	0.03%	485
2020 Q4	$1.08M	Sell	11,292 -5,368	-32%	-$518K	0.08%	326
2020 Q3	$1.6M	Buy	+16,660	New	+$1.93M	0.1%	271

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Duality Advisers's NBIX Position: Q2 2023 in Review

Duality Advisers sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 20,844 shares — an estimated $2.11M sold.

Duality Advisers first reported a position in NBIX in Q3 2020 and held it in 6 quarters. The position peaked at $2.11M in Q1 2023. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Duality Advisers reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Duality Advisers sold 20,844 Neurocrine Biosciences shares in Q2 2023, an estimated $2.11M.
Duality Advisers first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 6 quarters.
Duality Advisers's Neurocrine Biosciences position peaked at $2.11M in Q1 2023.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Duality Advisers's 13F filing for Q2 2023, filed 31 Jul 2023.